Translate

U.S. Industry Bacterial Conjunctivitis Drugs Industrial Trend and Market Demand - Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 - 2024

"Bacterial Conjunctivitis Drugs Market - U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 - 2024" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. Majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity. This study provides market analysis for various antibacterial drug classes used for the treatment of bacterial conjunctivitis. The stakeholders of this study comprise established pharmaceutical companies involved in the commercialization of antibacterial drugs as well as new participants who wish to enter the U.S. market.


This market study provides a complete analysis of the bacterial conjunctivitis drugs market in the U.S. and helps in identifying various market governing factors. The market overview section provides exhaustive information of the incidence rate of bacterial conjunctivitis, list of API manufacturers, patent challenges, market trends such as drivers, restraints, and growth opportunities that currently control the dynamics of the overall market.

The section also recommends and predicts the future conditions of the market. Market strategy tools such as event impact assessment and Porter’s Five Forces analysis have also been incorporated in this report to provide balanced analysis about the level of competition within the bacterial conjunctivitis drugs market in the U.S. Executive summary provided in the report encapsulates comprehensive insights about every segment considered in this study. Besides, it includes a market snapshot, which offers a glimpse into the current scenario of the bacterial conjunctivitis drugs market in the U.S. in terms of current and future market size along cumulative growth rate.

Additionally, this study includes a regulatory framework segment wherein the overall regulatory scenario of the U.S. drugs policy has been described. Participant analysis tools such as market share analysis have also been included in the market overview section of the report to deliver a broad spectrum of the overall market scenario in the bacterial conjunctivitis drugs market in the U.S.

The bacterial conjunctivitis drugs market in the U.S. has been segmented based on various antibacterial drug classes. The market is segmented into major types of antibacterial drugs such as fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones segment has been sub-segmented into ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and besifloxacin. Aminoglycosides has been sub-segmented into tobramycin and gentamycin. Macrolides has been divided into erythromycin and azithromycin. The others segment is analyzed cumulatively, considering bacitracin, fusidic acid and ceftriaxone within this class. The market size for the period from 2012 to 2024 has been provided for each of the major drug classes mentioned above in terms of USD million.


Along with the market size that were projected considering 2013 as the base year and 2012 as the historical year, the CAGR (%) of each market segment for the forecast period from 2012 to 2018 and 2018 to 2024 have also been provided.


The report concludes with detailed profiles of leading players in the bacterial conjunctivitis drugs (antibacterials) market in the U.S. The study profiles the companies in terms of overview, financial overview, product portfolio, business strategies, and recent developments. Major organizations profiled in this report include Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. Additionally, market share analysis that has been provided in context with the major pharmaceuticals operating in the market would help new participants to understand the key business perceptions and frameworks and to identify the specific product lines of the existing companies to establish a strong foothold in the bacterial conjunctivitis drugs market in the U.S.


** The U.S. bacterial conjunctivitis drugs market is segmented as follows:
– U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
  • Fluoroquinolones
  • Ciprofloxacin
  • Ofloxacin
  • Levofloxacin
  • Moxifloxacin
  • Gatifloxacin
  • Besifloxacin
  • Aminoglycosides
  • Tobramycin
  • Gentamycin
  • Macrolides
  • Erythromycin
  • Azithromycin
  • Others


– U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
  • Vancomycin Ophthalmic Ointment
  • Early Stage (Phase I and Phase II trials) – Tabular Representation

– Table of Content


Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions


Chapter 2 Executive Summary
2.1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market


Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview
3.1 Market Dynamics and Overview
3.2 Incidence Rate of Bacterial Conjunctivitis in the U.S.
3.3 Market Drivers
3.3.1 Rising Incidence of Ophthalmic Bacterial Infection
3.3.2 Susceptibility Among Various Age Groups Ranging from Neonates to Geriatrics
3.4 Market Restraints
3.4.1 Increasing Genericization of Antibacterial Drugs Could Lead to a Crowded and Unprofitable Market
3.4.2 Upcoming Patent Expirations likely to Hinder Market Growth
3.4.3 Burgeoning Multi-Drug Resistant Bacterial Strains Expected To Hinder Market Growth
3.5 Market Opportunities
3.5.1 Implementation of Product Development Partnerships (PDPs) Business Models
3.5.2 Focus on Designing and Producing Combination Drug Products
3.6 Event Impact Assessment: U.S. Bacterial Conjunctivitis Market
3.7 Regulatory Framework
3.8 Patents and Patent Challenges: Overview
3.9 List of API Manufacturers
3.10 Key Discontinued Products: U.S. Bacterial Conjunctivitis Drugs Market
3.10.1 Oxytetracycline/Polymyxin B
3.10.2 Sulfisoxazole Ophthalmic
3.10.3 Phenylephrine/Sulfacetamide Sodium
3.10.4 Chloramphenicol
3.11 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Type
3.12 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)


Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
4.1 Overview
4.1.1 Recommended Dosages for Treatment of Bacterial Conjunctivitis
4.1.2 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 – 2024 (USD Million)
4.2 Fluoroquinolones
4.2.1 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)
4.2.2 Ciprofloxacin
4.2.2.1 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.2.3 Ofloxacin
4.2.3.1 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.2.4 Levofloxacin
4.2.4.1 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.2.5 Moxifloxacin
4.2.5.1 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.2.6 Gatifloxacin
4.2.6.1 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.2.7 Besifloxacin
4.2.7.1 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.3 Aminoglycosides
4.3.1 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)
4.3.2 Tobramycin
4.3.2.1 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.3.3 Gentamycin
4.3.3.1 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.4 Macrolides
4.4.1 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)
4.4.2 Erythromycin
4.4.2.1 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.4.3 Azithromycin
4.4.3.1 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)
4.5 Others (Bacitracin, Doxycycline, Polymyxin, and Fusidic Acid)
4.5.1.1 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 – 2024 (USD Million)


Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
5.1 Overview
5.2 Vancomycin Ophthalmic Ointment
5.2.1 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 – 2024 (USD Million)
5.3 Early Stage (Phase I and Phase II trials) – Tabular Representation


Chapter 6 Recommendations
Chapter 7 Company Profiles
7.1 Actavis plc (now Allergan plc)
7.1.1 Company Overview
7.1.2 Financial Overview
7.1.3 Product Portfolio
7.1.4 Business Strategies
7.1.5 Recent Developments
7.2 Akorn, Inc.
7.2.1 Company Overview
7.2.2 Financial Overview
7.2.3 Product Portfolio
7.2.4 Business Strategies
7.2.5 Recent Developments
7.3 Bayer AG
7.3.1 Company Overview
7.3.2 Financial Overview
7.3.3 Product Portfolio
7.3.4 Business Strategies
7.3.5 Recent Developments
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.2 Financial Overview
7.4.3 Product Portfolio



Comments

Post a Comment